Trial · NCT00550459
Trial comparisons22
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 20 of 22
Download this page as JSON| Comparison | Source |
|---|---|
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN) | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Pulse Rate | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Blood Pressure | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT) | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Body Temperature | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Vital Sign Abnormalities: Body Weight | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Hematology Laboratory Abnormalities: Neutrophils | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI) | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec | Trial comparisons |
| Tolvaptan (15-60 mg) vs Placebo: Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec) | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00550459/comparisons